Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
|
|
- Marshall Young
- 5 years ago
- Views:
Transcription
1 Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
2 Conflict of Interest Statement German Research Council German Ministry of Education and Reserach EU Addex Alder Allergan Almirall Amgen Astra-Zeneca Bayer BMS Böhringer- Ingelheim Chordate Coherex CoLucid Eisai Electrocore Endo Pharmac. GSK Janssen-Cilag J&J Labrys Lilly MAP Menarini Medtronic MSD Neuroscore Novartis Novo Nordisk Pfizer Sanofi-Aventis Schering Solvay St. Jude Medical Teva Weber & Weber Wyeth
3 Why Clinical Trials? The only way to evaluate the efficacy of a drug, device or procedure Evaluate safety and tolerability Prerequisite for approval by health authorities Prerequisite for reimbursement IHS published guidelines on the conduct of controlled trials Tfelt-Hansen P, Diener HC et al, Cephalalgia 2012;32:6-38 3
4 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 4
5 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 5
6 Choice of primary endpoint in migraine trials FDA and EMA requirements In trials investigating the efficacy of drugs for the treatment of acute migraine attacks: Pain free after 2 hours Free of nausea Free of vomiting Free of photophobia Free of phonophobia Requires that symptoms are present at time of drug intake 6
7 Choice of primary endpoint in migraine trials My proposal In trials investigating the efficacy of drugs for the treatment of acute migraine attacks: Pain free after 2 hours Relief from the most bothersome additional symptom Endpoint is more relevant for patients 7
8 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 8
9 Treatment of migraine attacks and placebo How does expectation affect the treatment outcome? Kam-Hansen et al, Science Translational Medicine, 2014: 6(1):218ra5. doi: /scitranslmed
10 Study design 6 migraine attacks were treated, information given alternated Kam-Hansen et al, Science Translational Medicine, 2014: 6(1):218ra5. doi: /scitranslmed
11 Effect on expectation on the treatment success 50% of the treatment response is driven by expectation Kam-Hansen et al, Science Translational Medicine, 2014: 6(1):218ra5. doi: /scitranslmed
12 Zolmitriptan in the treatment of migraine attacks 1058 patients were included Primary endpoint: complete headache response (no recurrence) 39% zolmitriptan 38% sumatriptan 32% placebo Zolmitriptan and sumatriptan are not effective???? 12
13 Zolmitriptan for the treatment of acute migraine attacks 13
14 Placebo in randomized trials Placebo killed the study 14
15 Placebo in randomized headache trials Conclusions Placebo is needed in efficacy trials We need to know and control factors influencing the placebo response Uneven randomization Expectation Particular populations: children and adolescents 15
16 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 16
17 Are we sure that both drugs are superior to placebo in this population?
18 PREEMPT Pooled Analysis: ~70% of Patients* Achieved 50% Reduction in Headache Days at 56 Weeks 1 Headache Days/28 Days (Mean Change From Baseline) Headache Days/28 Days Change in Headache Days: Primary Endpoint 2 Week Week 24 Primary Endpoint Botulinum Toxin Type A Placebo -6 p< p<0.001 p<0.001p<0.001 Double-Blind Phase p<0.001 p<0.001 p<0.001 p=0.008p=0.01 p=0.007 p=0.047 p=0.019 p=0.011 p=0.019 Open-Label Phase How would Botox compare to topiramate? 18
19 a Similar efficacy for topiramate and propranolol 19
20 Combination analgesics for acute migraine attacks 1 active, 4 comparators and 1 placebo 20
21 a 21
22 Conclusion Both trials in the treatment of acute migraine attacks and migraine prevention require placebo control and a comparator Exceptions are trials which recruit treatment refractory patients 22
23 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 23
24 Telcagepant for the treatment of menstrual migraine Study terminated due to liver toxicity 24
25 Safety trials Conclusions Open label safety trials should run parallel to randomized phase 2 and phase 3 trials 25
26 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 26
27 Onabotulinumtoxin A in chronic migraine Trial missed the primary endpoint 27
28 aa Trial was positive on the primary endpoint 28
29 Choice of primary endpoint in migraine prevention Conclusions The preferred primary endpoint is either migraine days or headache days 29
30 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 30
31 Headache Days/28 Days (Mean Change From Baseline) Headache Days/28 Days 31 PREEMPT Pooled Analysis: Mean Change From Baseline in Headache Days (Primary) At Week 56, ~70% of patients achieved 50% reduction in headache days (from baseline) Week Week 24 Primary Endpoint BOTOX Placebo -6 p < p < p < p < p < p < Double-Blind Phase p < p = p = 0.01 p = p = p = p = p = Open-Label Phase Mean ± standard error. The double-blind phase included 688 subjects in the BOTOX group and 696 in the placebo group. Headache days at baseline: 19.9 BOTOX group vs 19.8 placebo group, p= Aurora SK et al. Presented at IHC 2009.
32 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 32
33 Pro Comparator Allows for comparison with other trials and substances Sensitivity test
34 Contra active comparator New preventive therapies will be used in patients who Failed approved preventive therapy (efficacy) Had contraindications Did not tolerate treatment
35 Contra Comparator Increased sample size Requires test of prior treatment failure (easy in treatment of acute attacks) Which comparator to choose? Patients will only be prepared to participate in a trial with injectable medication if they see a realistic chance to get active drug
36 Active Comparator Select adherence as the primary endpoint e.g. topiramate versus new drug for 6 months Offer patients blinded cross-over Offer patients long-term open-label treatment after randomized portion of trial
37 Trials in treatment refractory patients Conclusions Do we need to establish treatment failure prospectively? Experience from the zolmitriptan trial No need for a comparator 37
38 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 38
39 Migraine prevention trials Age groups Children 6-11 years Adolescents years Very difficult to recruit children in trials with injectable medication and biologicals Sample size almost impossible to estimate
40 Primary Endpoint Migraine days Headache days Children have difficulties to distinguish headache from migraine Adolescents are able to differentiate
41 Duration of Placebo Phase 3 months versus 6 months 3 months is enough Almost all recent trials showed a stable difference between active drug and placebo after 3 months Open-label phase for 9 months for all study participants recommended
42 Active comparator Active comparator versus placebo alone Parents of children and adolescents willing to participate in a randomized trial will only be prepared to do so if available treatments have failed Unethical to expose patients to a treatment that was not tolerated or was ineffective before
43 Treatment trials in children and adolescents Conclusions Randomized, placebo-controlled trials are requested by FDA and EMA Almost impossible to do in children Consider large placebo effect 43
44 Overview Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 44
45 A randomized trial to investigate what happens if prophylaxis is terminated 45
46 Cessation trials can teach us on the course of migraine 46
47 End of treatment trials Conclusion Important information to see whether a rebound occurs 47
48 Final conclusions Choice of primary endpoint in migraine trials Requirement for placebo Treatment comparator Safety trials Primary endpoint in migraine prevention trials Open-label long-term follow-up Trials in refractory headache Trials in children and adolescents Investigation of treatment termination 48
Stroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
More informationPer cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT
Migraine 1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA 2 Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA 3 Department of Neurology and Neurological
More informationIdentification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database
doi:10.1111/j.1468-2982.2007.01457.x Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database H-C Diener 1, DW Dodick 2, PJ Goadsby 3, RB Lipton 4, M
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationEditorial Team Conflict of Interest Statements
Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,
More information1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division
ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,
More informationTriptans: Nonresponse, Recurrence, and Serious AEs for Many Patients
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationDevelopment and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan
J Headache Pain (2008) 9:359 365 DOI 10.1007/s10194-008-0070-6 ORIGINAL Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan Hans-Christoph
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationISSN doi: /head.13327
Headache VC 18 The Authors Headache: The Journal Head and Face Pain published by Wiley Periodicals, Inc. on behalf American Headache Society ISSN 17-8748 doi:.1111/head.13327 Research Submission Use Most
More informationHans-Christoph Diener 1*, Morris Gold 2 and Martina Hagen 3
Diener et al. The Journal of Headache and Pain 2014, 15:76 RESEARCH ARTICLE Open Access Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone
More informationSpecific Objectives A. Topics to be lectured and discussed at the plenary sessions
Specific Objectives A. Topics to be lectured and discussed at the plenary sessions 0. Introduction: Good morning ICHD-III! Let s start at the very beginning. When you read you begin with A-B-C, so when
More informationBMS for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial
BMS-927711 for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial Ronald Marcus, MD Chief Medical Officer Spinifex Pharmaceuticals Migraine: Case Study
More informationRichard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationThe best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017
Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid
More informationI have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.
I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationJoel R. Saper, 1 Richard B. Lipton, 2 David B. Kudrow, 3 Joe Hirman, 4 David W. Dodick, 5 Stephen Silberstein, 6 George Chakhava, 7 Jeff Smith 8
Primary Results of PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More information6/2/2017. Objectives. Statement of Problem: Migraine Headaches Are Common. Chronic Headache In Pediatrics, Botox and Beyond
Chronic Headache In Pediatrics, Botox and Beyond Ken Mack MD PhD Mayo Clinic 2015 MFMER slide-1 Objectives Understand pediatric chronic headache presentations Review evidence for the treatment of chronic
More information2 nd Resubmission. 13 January 2017
2 nd Resubmission botulinum toxin A, 50 Allergan units, 100 Allergan units, 200 Allergan units, powder for solution for injection (Botox ) SMC No. (692/11) Allergan Limited 13 January 2017 The Scottish
More informationCrossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine
Original Paper Eur Neurol 2003;49:20 29 DOI: 10.1159/000067018 Received: March 13, 2002 Accepted: September 10, 2002 Crossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine
More informationPrevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.
Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology
More informationMark W. Green, MD, FAAN
Mark W. Green, MD, FAAN Professor of Neurology, Anesthesiology, and Rehabilitation Medicine Director of Headache and Pain Medicine Icahn School of Medicine at Mt Sinai New York Pain-sensitive structures
More informationIntroduction. Original Article
Original Article Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study Cephalalgia 0(0) 1 11! International
More informationARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract
Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent
More informationGuidelines for controlled trials of drugs in migraine: second edition
Guidelines for controlled trials of drugs in migraine: second edition International Headache Society Clinical Trials Subcommittee. Committee members: P Tfelt-Hansen (Chairman) (Denmark), G Block (USA),
More informationDisclosure. Learning Objectives 11/10/2017. The Best and Most Interesting Research from Last Year Cephalalgia
The Best and Most Interesting Research from Last Year Cephalalgia David W. Dodick, M.D. Department of Neurology Mayo Clinic Scottsdale Arizona Disclosure Consulting services: Acorda, Allergan, Amgen, Alder,
More informationDubai Standards of Care (Migraine)
Dubai Standards of Care 2018 (Migraine) Preface Migraine is one of the most common problem dealt with in daily practice. In Dubai, the management of migraine is done through various different strategies.
More informationManagement of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSIGN on the pharmacological management of migraine
GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management
More informationValue of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
J Headache Pain (2006) 7:27 33 DOI 10.1007/s10194-006-0266-6 ORIGINAL Julio Pascual Hans-Christoph Diener Hélène Massiou Value of postmarketing surveillance studies in achieving a complete picture of antimigraine
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationRimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, Biohaven
Rimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, 2018 1 Forward-Looking Statement This presentation contains forward-looking statements, including: statements about our plans to develop
More informationOnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study The Harvard community has made this article openly available. Please share how this access benefits you. Your story
More informationLost in Translation: Making Sense of Clinical Treatment Guidelines
Lost in Translation: Making Sense of Clinical Treatment Guidelines Charles E. Argoff, MD, CPE Disclosures: Charles Argoff Financial Disclosure: Consultant: Teva, Daiichi Sakyo, Pfizer, Nektar, Purdue,
More informationMigraine - whats on the horizon
Managing your migraine Edinburgh Saturday 10 th March 2018 Migraine - whats on the horizon Alok Tyagi Consultant Neurologist Glasgow Disclaimer I have received from Janssen Cillag, GSK, Allergan, Electrocore,
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationDifferentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD
Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD University of California, San Francisco San Francisco, CA King's College London London, England Learning
More informationIshaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert
Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Childhood headache: Is it really difficult to manage? It shouldn t be... But it can be...
More informationJessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital
Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Honorarium from Current Pain and Headache Reports; Section Editor Unusual
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationImproving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
Original Article Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM) Cephalalgia 2016, Vol. 36(3) 203 215! International Headache Society 2015 Reprints
More informationUpdate on clopidogrel and dual anti-platelet therapy: neurology
European Heart Journal Supplements (2006) 8 (Supplement G), G15 G19 doi:10.1093/eurheartj/sul049 Update on clopidogrel and dual anti-platelet therapy: neurology Hans-Christoph Diener Department of Neurology,
More informationClinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.
OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: occipital_nerve_stimulation 8/2010 5/2017 5/2018 5/2017 Description of Procedure or Service Occipital nerve
More informationAntiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS
Antiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS Is There Still a Role for IV Antiplatelet Agents (Cangrelor, GPIIbIIIA inhibitors)? François Schiele, MD, PhD Department of Cardiology, University
More informationCurrent Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN
Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality
More informationIndustry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
More informationDrug Class Review Triptans
Drug Class Review Triptans April 2013 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationDrug Class Review on Triptans
Drug Class Review on UPDATED FINAL REPORT #1 December 2003 Mark Helfand, MD, MPH Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of Contents Introduction
More informationAn Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California
An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect
More informationQuality Indicators in Chronic Pain Management
Disclosures (2008-2013): 1. Employment: Heidelberg University 2. Advisor: Allergan, Astellas, Astra-Zeneca, Boehringer Ingelheim, Galderma, Glaxo Smith Kline, Grünenthal, Lilly, Merz, Merck-Sharpe & Dohme,
More informationLasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine
(200 mg and 100 mg) Compared to for Acute Treatment of Migraine Bernice Kuca, M.S. 1 ; Linda A. Wietecha, B.S.N., M.S. 2 ; Paul H. Berg, M.S. 2 ; Sheena K. Aurora, M.D. 2 1 CoLucid Pharmaceuticals, Inc.,
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationCOMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS
ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900
More informationDrug Class Review on the Triptans
Drug Class Review on the Final Report March 7, 2003 Expires October 31, 2003 Mark Helfand, MD, MPH Kim Peterson, MS Produced by Oregon Health & Science University 3181 SW Sam Jackson Park Road Mailcode:
More informationDoes analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
DOI 10.1186/s40064-015-1386-8 RESEARCH Open Access Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse Fayyaz Ahmed *, Hassan
More informationPaediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition
Paediatric headaches Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services Brevity, levity, repetition Paediatric)headache?)! Headache!in!children!is!not!that!common.!The!question!is!which!headaches!do!I!
More informationCalcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value
Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Background Draft Background and Scope December 4, 2017
More informationÇiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE
Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More informationDecision for fibrinolysis or primary PCI in the prehospital phase
Decision for fibrinolysis or primary PCI in the prehospital phase Nicolas Danchin, Hôpital Européen Georges Pompidou, Paris, France Disclosures Research grants: Astrazeneca, Eli-Lilly, GSK, Merck, Novartis,
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationPage: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)
Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)
More informationGet ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention
Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Amanda Janisch, PharmD PGY2 Ambulatory Care Pharmacy Resident MCHS SWMN, Mankato, MN 2018 MFMER slide-1 Disclosures No financial interest
More informationProposed Project Scope. OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice
Proposed Project Scope OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice May 2018 1. BACKGROUND AND RATIONALE Migraine is a common, debilitating
More informationMEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache
MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended
More informationAn economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D
An economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D Record Status This is a critical abstract of an economic evaluation that meets the
More informationDaniel Kassicieh, DO, FAAN
Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraine is a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality but high morbidity 38 million Americans
More informationA Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic Migrainehead_
Headache 2010 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2010.01796.x Published by Wiley Periodicals, Inc. Research Submission A Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: surgical_deactivation_of_migraine_headache_trigger_sites 10/2012 5/2017 5/2018 5/2017 Description of Procedure
More information...SELECTED ABSTRACTS...
The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationOnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
731521TAN0010.1177/1756285617731521Therapeutic Advances in Neurological DisordersC-C Chiang and AJ Starling research-article2017 Therapeutic Advances in Neurological Disorders Review OnabotulinumtoxinA
More informationAleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia
European Headache School Belgrade 2012 MEDICATION OVERUSE HEADACHE Aleksandra Radojičić Headache Center, Neurology Clinic, Clinical Center of Serbia Historical data First cases were described in XVII century
More informationMigraine Treatment What you need to know
Migraine Treatment What you need to know DR NICOLE LIMBERG ST ANDREWS PLACE SPRING HILL www.migrainespecialist.com.au Migraine what is it? Primary neurobiological condition Waves of reduced brain activity
More informationMigraine and Patent Foramen Ovale (PFO)
Migraine and Patent Foramen Ovale (PFO) Hans-Christoph Diener Senior Professor of Clinical Neurosciences Department of Neurology and Headache Center University Essen Topics Prevalence of PFO Is migraine
More informationSubject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s):
Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018 Policy Number: MCP-320 Revision Date(s): Review Date(s): MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended
More informationPROGRAM SYLLABUS. Jointly provided by Potomac Center for Medical Education and Rockpointe
PROGRAM SYLLABUS Jointly provided by Potomac Center for Medical Education and Rockpointe This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding
More informationSUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationWhat is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary
What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going
More informationOnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
Pedraza et al. SpringerPlus (2015) 4:176 DOI 10.1186/s40064-015-0957-z a SpringerOpen Journal RESEARCH Open Access OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with
More informationin patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
More informationMaternity. Migraine in pregnancy Information for women
Maternity Migraine in pregnancy Information for women You have been given this leaflet as you have a diagnosis of migraines. It contains advice to help you manage your migraines safely during your pregnancy.
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More information10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe?
Disclosures MIGRAINE PROPHYLAXIS Erenumab-aooe (AIMOVIG TM ) Calcitonin Gene Related Peptide Receptor Antagonist No conflicts of interest to disclose Chelsey Roscoe, PharmD PGY1 Resident - CTVHCS 2 3 Definitions
More informationMIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More information